Anavex Life Sciences (STU:12X1) Total Stockholders Equity : €124.16 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences Total Stockholders Equity?

Anavex Life Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €124.16 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Anavex Life Sciences's Book Value per Share for the quarter that ended in Mar. 2024 was €1.48. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Anavex Life Sciences's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.

Anavex Life Sciences Total Stockholders Equity Historical Data

The historical data trend for Anavex Life Sciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Total Stockholders Equity Chart

Anavex Life Sciences Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Stockholders Equity

Get a 7-Day Free Trial

18.42

23.12

128.20

143.92

132.92

Anavex Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															135.58	135.46	132.92	124.32	124.16

Anavex Life Sciences (STU:12X1) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Anavex Life Sciences's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(124.161	-	0)	/	83.6162
	=	1.48

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Anavex Life Sciences's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	124.161
	=	0.00

Anavex Life Sciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences (STU:12X1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

AVXL:USA 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (STU:12X1) Headlines

No Headlines